Pancreatic Cancer Research

Clinical trialPhase 2Completed

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

An Open-Label, Phase II Study of Cabozantinib (XL184) in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Outcome
Results posted; no analysis attached
Phase
Phase 2
Status
Completed
Study type
Interventional
Start
July 2012
Ended
December 2023
Enrollment
61 participants
Sites
2
Primary outcomes
Objective Response Rate (ORR)
Sponsor type
Academic / other
Results posted
20 July 2023
Last update
5 March 2024

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 5 March 2024
ORR
Objective Response Rate (ORR)Metastatic or Unresectable PNET: 3 of 20Metastatic or Unresectable Carcinoid: 7 of 41Values: ParticipantsTime frame: Imaging was performed cycles 2,4,6 every 8 weeks for the first 24 weeks, then every 3rd cycle every 12 weeks until progression or EOT. Median treatment duration was 8 cycles for the Carcinoid cohort and 12.5 cycles for the PNET cohort. Cycle=28 days.No analysis posted for this outcome (outcome 1)
Participants
Metastatic or Unresectable PNET: 20 started, 0 completedMetastatic or Unresectable Carcinoid: 41 started, 0 completed
Serious adverse events
Metastatic or Unresectable PNET: 15 of 20Metastatic or Unresectable Carcinoid: 24 of 41Participants with at least one serious adverse event, of those at risk, as posted
2 secondary outcomes
PFS · Progression Free Survival (PFS)
Metastatic or Unresectable PNET 21.1 (8.6 to 32.0), n=20; Metastatic or Unresectable Carcinoid 17.6 (8.3 to 23.8), n=41 [median months, 95% Confidence Interval]
OS · Overall Survival (OS)
Metastatic or Unresectable PNET 37.3 (14.5 to 70.7), n=20; Metastatic or Unresectable Carcinoid 36.1 (20.6 to 65.5), n=41 [median months, 95% Confidence Interval]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

Cabozantinib works by blocking the growth of new blood vessels that feed a tumor. In addition to blocking the formation of new blood cells in tumors, cabozantinib also blocks pathways that may be responsible for allowing cancers cells to become resistant to other "anti-angiogenic" drugs. Cabozantinib has been studied or is being study in research studies as a possible treatment for various types of cancer, including prostate cancer, brain cancer, thyroid cancer, lung cancer, and kidney cancer. In this research study, the investigators wish to learn if cabozantinib is effective in treating patients with pancreatic neuroendocrine and carcinoid tumors.

Detailed description public domain (ClinicalTrials.gov)

Subjects will take cabozantinib orally, once per day, in cycles of 28 days. During each cycle subjects will have the following procedures: * Physical examination, including measurement of weight and vital signs * Questions regarding any side effects * Blood sample (about 1 tablespoon) for routine laboratory tests of blood cell counts, blood chemistries, organ function and blood clotting * Blood sample (about 4 tablespoons) for research test to measure biomarkers to assess the response to study drug * Urine sample for routine urine tests to monitor health On Day 15 (beginning of week 3) during the first 3 cycles: * Physical examination, including measurement of weight and vital signs * Questions regarding any side effects * Blood sample (about 1 tablespoon) for routine laboratory tests of blood cell counts, blood chemistries, organ function and blood clotting * Blood sample (about 4 tablespoons) for research test to measure biomarkers to assess the response to study drug Subjects will receive a CT scan or MRI every two cycles (every two months) to evaluate disease.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Objective Response Rate (ORR) [Imaging was performed cycles 2,4,6 every 8 weeks for the first 24 weeks, then every 3rd cycle every 12 weeks until progression or EOT. Median treatment duration was 8 cycles for the Carcinoid cohort and 12.5 cycles for the PNET cohort. Cycle=28 days.]. Count Of Participants, Participants. Metastatic or Unresectable PNET (n=20): 3; Metastatic or Unresectable Carcinoid (n=41): 7.

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Progression Free Survival (PFS) [Restaging imaging was performed after cycles 2, 4, and 6 (every 8 weeks for the first 24 weeks), then every 3rd cycle (every 12 weeks) until disease progression or end of study treatment. Median follow-up is 89.1 months. Cycle = 28 days.]. Median, months (95% Confidence Interval). Metastatic or Unresectable PNET (n=20): 21.1 (8.6 to 32.0); Metastatic or Unresectable Carcinoid (n=41): 17.6 (8.3 to 23.8).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Survival (OS) [Median follow-up time of 89.1 months.]. Median, months (95% Confidence Interval). Metastatic or Unresectable PNET (n=20): 37.3 (14.5 to 70.7); Metastatic or Unresectable Carcinoid (n=41): 36.1 (20.6 to 65.5).